Simon Read - 10 Aug 2026 Form 4 Insider Report for Dianthus Therapeutics, Inc. /DE/ (DNTH)

Source evidence Original filing metadata and source links for verification. 5 source fields
SEC form
4
Accepted by SEC
11 Aug 2026, 17:10:21 UTC
Prior SEC filing
22 May 2026
Next SEC filing
19 Aug 2026
Source filing
View source filing
Reporting owner 1 detail
Reporting owner signature
/s/ Adam Veness, as attorney-in-fact for Simon Read

Key filing fact

Simon Read filed Form 4 for Dianthus Therapeutics, Inc. /DE/ (DNTH) on 11 Aug 2026.

Key facts

  • This page summarizes Simon Read's Form 4 filing for Dianthus Therapeutics, Inc. /DE/ (DNTH).
  • 8 reported transactions and 1 derivative row are listed below.
  • Accepted by SEC: 11 Aug 2026, 17:10.

Change

  • Previous filing in this sequence was filed on 22 May 2026.
  • Current net transaction value: -$304,232.

Research use

  • This tells you what this filing adds before you inspect full transaction and derivative tables.
  • You can trace every row back to the original SEC filing document.

Evidence

Filed on Form 4

Ownership activity is grounded in SEC Form 4 disclosures.

View source filing

Reporting Owners (1)

CIK 0001688199 Primary reporting owner

Read Simon

Relationship
Director
Address
C/O DIANTHUS THERAPEUTICS, INC., 7 TIMES SQUARE, 43RD FLOOR, NEW YORK
Signature
/s/ Adam Veness, as attorney-in-fact for Simon Read
Signature date
11 Aug 2026

Reported non-derivative transactions

Shares, units, or other non-derivative securities reported in this filing.

DNTH transaction

Common Stock

Options Exercise

Transaction value
Shares
+2,777
Change %
Price
$18.36*
Shares after
2,777
Date
10 Aug 2026
Ownership
Direct
Footnotes
F1
DNTH transaction

Common Stock

Sale

Transaction value
$7,498
Shares
-70
Change %
-2.5%
Price
$107.11
Shares after
2,707
Date
10 Aug 2026
Ownership
Direct
Footnotes
F1, F2
DNTH transaction

Common Stock

Sale

Transaction value
$79,721
Shares
-737
Change %
-27%
Price
$108.17
Shares after
1,970
Date
10 Aug 2026
Ownership
Direct
Footnotes
F1, F3
DNTH transaction

Common Stock

Sale

Transaction value
$90,537
Shares
-831
Change %
-42%
Price
$108.95
Shares after
1,139
Date
10 Aug 2026
Ownership
Direct
Footnotes
F1, F4
DNTH transaction

Common Stock

Sale

Transaction value
$29,909
Shares
-272
Change %
-24%
Price
$109.96
Shares after
867
Date
10 Aug 2026
Ownership
Direct
Footnotes
F1, F5
DNTH transaction

Common Stock

Sale

Transaction value
$52,194
Shares
-470
Change %
-54%
Price
$111.05
Shares after
397
Date
10 Aug 2026
Ownership
Direct
Footnotes
F1, F6
DNTH transaction

Common Stock

Sale

Transaction value
$44,373
Shares
-397
Change %
-100%
Price
$111.77
Shares after
0
Date
10 Aug 2026
Ownership
Direct
Footnotes
F1, F7

Reported derivative securities

Options, warrants, convertible securities, or similar derivative positions disclosed in the filing.

DNTH transaction Derivative

Stock Option (Right to Buy)

Options Exercise

Transaction value
Shares
-2,777
Change %
-11%
Price
$0.000000*
Shares after
22,223
Date
10 Aug 2026
Ownership
Direct
Underlying class
Common Stock
Underlying amount
2,777
Exercise price
$18.36
Footnotes
F1, F8
* marks a reported price that did not pass the local price check.

Additional SEC filing notes

Filing notes and footnotes

Rule 10b5-1 trading plan

These transactions were reported as open-market trades under a Rule 10b5-1 plan. The plan lets an insider set trading instructions in advance, which can reduce the risk of trading while in possession of material nonpublic information.

Original filing language: transaction made pursuant to a contract, instruction, or written plan intended to satisfy Rule 10b5-1(c).

Explanation of responses 8 footnotes

Footnote F1

The reported transaction was effected pursuant to a Rule 10b5-1 trading plan adopted on May 8, 2026.

Footnote F2

The price reported above is a weighted average price. The shares were sold in multiple transactions at prices ranging from $106.50 to $107.27, inclusive. The Reporting Person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the SEC, upon request, full information regarding the number of shares sold at each separate price within the range.

Footnote F3

The price reported above is a weighted average price. The shares were sold in multiple transactions at prices ranging from $107.54 to $108.53, inclusive. The Reporting Person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the SEC, upon request, full information regarding the number of shares sold at each separate price within the range.

Footnote F4

The price reported above is a weighted average price. The shares were sold in multiple transactions at prices ranging from $108.54 to $109.54, inclusive. The Reporting Person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the SEC, upon request, full information regarding the number of shares sold at each separate price within the range.

Footnote F5

The price reported above is a weighted average price. The shares were sold in multiple transactions at prices ranging from $109.55 to $110.50, inclusive. The Reporting Person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the SEC, upon request, full information regarding the number of shares sold at each separate price within the range.

Footnote F6

The price reported above is a weighted average price. The shares were sold in multiple transactions at prices ranging from $110.56 to $111.56, inclusive. The Reporting Person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the SEC, upon request, full information regarding the number of shares sold at each separate price within the range.

Footnote F7

The price reported above is a weighted average price. The shares were sold in multiple transactions at prices ranging from $111.57 to $111.80, inclusive. The Reporting Person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the SEC, upon request, full information regarding the number of shares sold at each separate price within the range.

Footnote F8

The shares of common stock underlying this stock option award vest as to one-third of the shares subject to the option on each of the first, second and third anniversaries of the date of grant, subject to the Reporting Person's continued service to the Issuer on each such vesting date.

We use cookies and similar technologies to provide certain features, enhance the user experience and, if you allow them, measure engagement and deliver advertising. Analytics and marketing storage stay off until you grant consent. By clicking on "Agree and continue", you declare your consent to the use of the selected optional cookies. Manage preferences to update or revoke optional consent for future visits. For more information, see our Privacy Policy .